Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-09

Clinical Trial Update: Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating fruquintinib plus irinotecan for advanced gastric cancer is in an unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fruquintinib (fruquintinib)
  • Irinotecan (Irinotecan)

Snippet

Sponsor: Fujian Medical University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN